GLP-1 (Glucagon Like Peptide-1) Analogues for the Treatment of Type II Diabetes

Abstract

Glucagon-like peptide-1 (GLP-1) is a pharmacologically active hormone with a multiplicity. GLP-1's metabolic effects include glucose-based stimulation of insulin secretion, reduced gastric emptying, inhibition of dietary intake, increased normal and diuresis and rodent b cell control. GLP-1 works cardiovascularly or neuroprotectively, reduces inflammation, apoptosis and impacts education, memory and behavioral care. GLP-1 receptor agonists are widely used for clinical treatment of type 2 diabetes, which is biochemically, engineered to improve power and sustain action. The clinical testing for the treatment of obesity is also performed with many GLP 1-based pharmacotherapies.This has contributed to the creation of GIP receptor agonist peptides, like chimerical peptides, which mimic GIP's inconsistency with GLP 1. In these two agents, glycaemic regulation is improved and weight loss is improved with complementary and regular supplementary effects.